Table 3. Anti-tumor activities of SFK inhibitors.

Drug	Examples of targets	Activities on tumor cells				Clinical trials
		Proliferation	Apoptosis	Invasion, Metastasis	Drug re-sensitivity
Bosutinib	SFKs, ABL, CAMK2G, TEC, STE20	Reduced [166, 167]	Increased [168]	Reduced [169, 170]	Restored [171]	CML [172] and breast cancer [173]
Dasatinib	SFKs, BCR/ABL, c-Kit, Ephrins, RTKs	Reduced [174–177]	Increased [178–180]	Reduced [181, 182]	Restored [123, 134]	Prostate [183] and breast [184, 185] cancer
Saracatinib	SFKs, BCR/ABL, EGFR	Reduced [186, 187]	Increased [132]	Reduced [188, 189]	Restored [190, 191]	Melanoma [192] and lung [193] cancer
PP2	SFKs, RIP2, CK1δ	Reduced [194]	Increased [195]	Reduced [196]	Restored [197]	Not tested
A-419259	SFKs	Reduced [118, 198]	Increased [118]	Reduced [198]	Not tested	Not tested
RK-20449	HCK	Reduced [142]	Increased [142]	Not tested	Not tested	Not tested
SU6656	SFKs, PGDF, BRSK2, AMPK, Aurora C, Aurora B, CaMKKβ	Reduced [199]	Increased [200]	Reduced [201]	Restored [66]	Not tested